原发性上皮性卵巢癌胚系BRCA1/2突变患者的真实世界临床结局
该真实世界研究分析了2011至2019年间接受减瘤手术的III/IV期高级别浆液性上皮性卵巢癌患者,其中612例已知胚系BRCA状态。胚系BRCA突变不影响术中疾病表现、手术复杂性、完全切除率或严重术后并发症,但突变患者无进展生存期和总生存期显著更长。完全切除仍是独立于BRCA状态的最重要预后因素。
要点
- 胚系BRCA状态不影响术中疾病表现、手术复杂性和完全切除率。
- 胚系BRCA突变患者无进展生存期和总生存期显著更长。
- 完全切除是上皮性卵巢癌最重要的预后因素,与BRCA状态无关。
核心结论
- 胚系BRCA状态对初次疾病表现、手术结果或术后并发症无影响。
- 胚系BRCA突变患者无进展生存期显著更长,但对长期预后的影响尚不明确。
- 完全切除是上皮性卵巢癌患者最重要的预后因素,独立于胚系BRCA状态。
研究设计与样本
- 回顾性分析2011年1月至2019年6月期间在单中心接受减瘤手术的连续上皮性卵巢癌患者。
- 纳入标准为III/IV期、高级别浆液性组织学且已知胚系BRCA状态的患者。
- 共1221例患者中50.1%(612/1221)确定了胚系BRCA状态,其中21.9%(134/612)存在胚系BRCA突变。
主要发现
- 胚系BRCA突变组与非突变组在中位年龄(p=0.001)和组织学类型(高级别浆液性:98.5% vs 76.2%,p<0.001)上存在显著差异。
- 完全切除率在胚系BRCA突变组为74.4%,非突变组为69.0%(p=0.274)。
- 严重术后并发症发生率在胚系BRCA突变组为12.0%,非突变组为19.1%(p=0.082)。
- 胚系BRCA突变组与非突变组的中位无进展生存期分别为31个月和22个月,中位总生存期分别为71个月和53个月。
- 调整已确立预后因素后,胚系BRCA突变是无进展生存期(HR 0.57,p<0.001)和总生存期(HR 0.64,p=0.048)的显著预后因素。
临床怎么用
- 术前已知胚系BRCA状态不影响手术决策,完全切除仍是手术目标。
- 胚系BRCA突变可作为预后评估的参考因素,提示无进展生存期和总生存期可能更长。
局限性
- 仅50.1%的患者确定了胚系BRCA状态,可能存在选择偏倚。
- 真实世界单中心回顾性设计,长期预后影响尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the clinical impact of germline (g)BRCA1/2-mutation on initial disease presentation, surgical implications, surgical morbidity and survival in patients with advanced epithelial ovarian cancer (EOC) undergoing debulking surgery (DS). METHODS: Data of all consecutive EOC patients with stage III/IV, high-grade serous disease and known gBRCA1/2 status (gBRCA; non-gBRCA), who underwent DS at our department between 01/2011 and 06/2019 were analyzed. Associations between gBRCA-status and severe postoperative complications and survival were analyzed. RESULTS: gBRCA-status was determined in 50.1% (612/1221) of all patients. gBRCA was present in 21.9% (134/612). Significant differences were observed in terms of median age (p = 0.001) and histology (high-grade serous histology gBRCA: 98.5%, non-gBRCA 76.2%; p < 0.001). gBRCA-status had no impact on intraoperative disease presentation, surgical complexity or complete resection rate (gBRCA: 74.4%, non-gBRCA: 69.0%; p = 0.274). gBRCA-status was not predictive for severe postoperative complication (gBRCA: 12.0%, non-gBRCA: 19.1%; p = 0.082). Median PFS and OS was 31/22 and 71/53 months in patients with/without gBRCA-mutation, respectively. gBRCA was a significant prognostic factor for PFS (HR 0.57 p < 0.001) and for OS (HR 0.64, p = 0.048) after adjusting for established prognostic factors. CONCLUSIONS: gBRCA-status had no impact on initial disease presentation, surgical results or postoperative complications. gBRCA patients have a significantly longer PFS but the impact on the long term prognosis is unclear. Complete resection remains the most important prognostic factor in patients with EOC independent of gBRCA-status.
引用
- Ataseven B, Tripon D, Schwameis R, et al. Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data. Gynecol Oncol. 2021. PMID: 34565600. doi:10.1016/j.ygyno.2021.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。